Society of Family Planning Clinical Recommendations: Contraceptive Care in the Context of Pandemic Response

Bianca M Stifani, Tessa Madden, Elizabeth Micks, Ghazaleh Moayedi, Jessica Tarleton, Lyndsey S Benson, Bianca M Stifani, Tessa Madden, Elizabeth Micks, Ghazaleh Moayedi, Jessica Tarleton, Lyndsey S Benson

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has posed a burden to healthcare systems around the world and has changed the way people access health services, including contraception. This document sets forth guidance from the Society of Family Planning for providing contraceptive care in the context of the COVID-19 pandemic, including when access to healthcare is restricted due to pandemic response. It also outlines the role of telehealth for providing contraceptive care beyond the pandemic. Clinicians can use synchronous telemedicine visits and other forms of telehealth to provide many aspects of contraceptive care. Both audio-video and audio-only visits are acceptable forms of telemedicine. Access to permanent contraception should be maintained, especially in the postpartum period. Combined hormonal contraceptive (CHC) users who have asymptomatic or mild COVID-19 infection may continue their contraceptive method, while those admitted to the hospital with severe infection should suspend CHC use until they are clinically recovered. CHC users who take Paxlovid for mild-moderate COVID-19 infection can consider a back-up contraceptive method for the duration of therapy, but clinically relevant drug interactions are unlikely. Future research should examine contraceptive outcomes in people who receive care via telemedicine; and access to telemedicine among historically excluded populations such as adolescents, people of color, people of low socioeconomic status, disabled people, or people who do not speak English as a primary language.

Keywords: COVID-19; contraception; guideline; pandemic; telehealth; telemedicine.

Copyright © 2022. Published by Elsevier Inc.

Figures

Box 1
Box 1
How to be reasonably certain that a woman is not pregnant

References

    1. CDC Covid Data Tracker. 2022 [accessed April 1, 2022]
    1. Webb Hooper M, Nápoles AM, Pérez-Stable EJ. COVID-19 and Racial/Ethnic Disparities. JAMA. 2020;323(24):2466–2467.
    1. Gupta AH. Why Some Women Call This Recession a ‘Shecession.’. The New York Times. 2020 May 9
    1. Terrell K. AARP; 2020. 10 Occupations hit hardest by the pandemic. [accessed April 1, 2022]
    1. Benson LS, Madden T, Tarleton J, Micks EA. Society of Family Planning interim clinical recommendations: contraceptive provision when healthcare access is restricted due to pandemic response. April 1, 2022 Available from. acccessed.
    1. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1641–1647. doi: 10.15585/mmwr.mm6944e3.
    1. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020;370:m3320. doi: 10.1136/bmj.m3320.
    1. Lokken EM, Huebner EM, Taylor GG, Hendrickson S, Vanderhoeven J, Kachikis A, et al. Disease severity, pregnancy outcomes, and maternal deaths among pregnant patients with severe acute respiratory syndrome coronavirus 2 infection in Washington State. Am J Obstet Gynecol. 2021;225:77. doi: 10.1016/j.ajog.2020.12.1221. e1-77.e14.
    1. DeBolt CA, Bianco A, Limaye MA, Silverstein J, Penfield CA, Roman AS, et al. Pregnant women with severe or critical coronavirus disease 2019 have increased composite morbidity compared with nonpregnant matched controls. Am J Obstet Gynecol. 2021;224:510. doi: 10.1016/j.ajog.2020.11.022. e1-510.e12.
    1. Di Mascio D, Khalil A, Saccone G, Rizzo G, Buca D, Liberati M, et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2020;2 doi: 10.1016/j.ajogmf.2020.100107.
    1. Metz TD, Clifton RG, Hughes BL, Sandoval G, Saade GR, Grobman WA, et al. Disease Severity and Perinatal Outcomes of Pregnant Patients With Coronavirus Disease 2019 (COVID-19) Obstet Gynecol. 2021;137:571–580. doi: 10.1097/AOG.0000000000004339.
    1. Coombe J, Kong F, Bittleston H, Williams H, Tomnay J, Vaisey A, et al. Contraceptive use and pregnancy plans among women of reproductive age during the first Australian COVID-19 lockdown: findings from an online survey. Eur J Contracept Reprod Heal Care Off J Eur Soc Contracept. 2021;26:265–271. doi: 10.1080/13625187.2021.1884221.
    1. Zhu C, Wu J, Liang Y, Yan L, He C, Chen L, et al. Fertility intentions among couples in Shanghai under COVID-19: A cross-sectional study. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 2020;151:399–406. doi: 10.1002/ijgo.13366.
    1. Micelli E, Cito G, Cocci A, Polloni G, Russo GI, Minervini A, et al. Desire for parenthood at the time of COVID-19 pandemic: an insight into the Italian situation. J Psychosom Obstet Gynaecol. 2020;41:183–190. doi: 10.1080/0167482X.2020.1759545.
    1. Kahn LG, Trasande L, Liu M, Mehta-Lee SS, Brubaker SG, Jacobson MH. Factors Associated With Changes in Pregnancy Intention Among Women Who Were Mothers of Young Children in New York City Following the COVID-19 Outbreak. JAMA Netw Open. 2021;4 doi: 10.1001/jamanetworkopen.2021.24273.
    1. Lindberg LD, VandeVusse A, Mueller J, Kirstein M. Early impacts of the COVID-19 pandemic: findings from the 2020 Guttmacher Survey of Reproductive Health Experiences. 2020 Available from. [accessed April 1, 2022]
    1. Centers for Medicare and Medicaid Services CMS Releases Recommendations on Adult Elective Surgeries, Non-Essential Medical, Surgical, and Dental Procedures During COVID-19 Response. 2020 March 18 Available from. [accessed April 1, 2022]
    1. World Health Organization; Geneva: 2020 June 1. Maintaining essential health services: operational guidance for the COVID-19 context, interim guidance, 1 June 2020. Available from. [accessed April 1, 2022]
    1. ACOG Joint Statement on Abortion Access During the COVID-19 Outbreak. 2020 March 18 Available from. [accessed April 1, 2022]
    1. Center for Reproductive Rights Access to Comprehensive Sexual and Reproductive Health Care is a Human Rights Imperative During the COVID-19 Pandemic. 2020 Available from. [accessed April 1, 2022]
    1. Ahmed S, Li Q, Liu L, Tsui AO. Maternal deaths averted by contraceptive use: an analysis of 172 countries. Lancet. 2012;380:111–125. doi: 10.1016/S0140-6736(12)60478-4.
    1. Amnesty International Why abortion and contraception are essential healthcare. 2020 April 22 Available from. [accessed April 1, 2022]
    1. Cox C, Amin K, Kamal R. How have health spending and utilization changed during the coronavirus pandemic? Health System Tracker. 2021 March 22 Available from. [accessed April 1, 2022]
    1. Garcia S, Albaghdadi MS, Meraj PM, Schmidt C, Garberich R, Jaffer FA, et al. Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States During COVID-19 Pandemic. J Am Coll Cardiol. 2020;75:2871–2872. doi: 10.1016/j.jacc.2020.04.011.
    1. Martin K, Kurowski D, Given P, Kennedy K, Clayton E. The impact of COVID-19 on the use of preventative health care. Health Care Cost Institute. 2021 April 16 Available from. [accessed April 1, 2022]
    1. Weigel G, Frederiksen B, Ranji U, Salganicoff A. Kaiser Family Foundation; 2020 December 2. How OBGYNs adapted provision of sexual and reproductive health care during the COVID-19 pandemic. Available from. [accessed April 1, 2022]
    1. Steenland MW, Geiger CK, Chen L, Rokicki S, Gourevitch RA, Sinaiko AD, et al. Declines in contraceptive visits in the United States during the COVID-19 pandemic. Contraception. 2021;104:593–599. doi: 10.1016/j.contraception.2021.08.003.
    1. Diamond-Smith N, Logan R, Marshall C, Corbetta-Rastelli C, Gutierrez S, Adler A, et al. COVID-19’s impact on contraception experiences: Exacerbation of structural inequities in women's health. Contraception. 2021;104:600–605. doi: 10.1016/j.contraception.2021.08.011.
    1. Balachandren N, Barrett G, Stephenson JM, Yasmin E, Mavrelos D, Davies M, et al. Impact of the SARS-CoV-2 pandemic on access to contraception and pregnancy intentions: a national prospective cohort study of the UK population. BMJ Sex Reprod Heal. 2021 doi: 10.1136/bmjsrh-2021-201164.
    1. WHO Telemedicine: Opportunities and developments in member states. 2010 Available from. [accessed April 1, 2022]
    1. Implementing Telehealth in Practice: ACOG Committee Opinion Summary, Number 798. Obstet Gynecol. 2020 doi: 10.1097/AOG.0000000000003672.
    1. Centers for Medicare & Medicaid Services Medicare telemedicine health care provider fact sheet. 2020 March 17 Available from. [accessed April 1, 2022]
    1. Stifani BM, Avila K, Levi EE. Telemedicine for contraceptive counseling: An exploratory survey of US family planning providers following rapid adoption of services during the COVID-19 pandemic. Contraception. 2021:103. doi: 10.1016/j.contraception.2020.11.006.
    1. Centers for Disease Control and Prevention COVID-19 integrated county view. 2022 Available from [accessed April 1, 2022]
    1. Health Resources and Services Administration Billing and coding Medicare Fee-for-Service claims. 2021 Available from. [accessed April 1, 2022]
    1. Chang JE, Lindenfeld Z, Albert SL, Massar R, Shelley D, Kwok L, et al. Telephone vs. Video Visits During COVID-19: Safety-Net Provider Perspectives. J Am Board Fam Med. 2021;34:1103–1114. doi: 10.3122/jabfm.2021.06.210186.
    1. Stifani BM, Smith A, Avila K, Boos EW, Ng J, Levi EE, et al. Telemedicine for contraceptive counseling: Patient experiences during the early phase of the COVID-19 pandemic in New York City. Contraception. 2021 doi: 10.1016/j.contraception.2021.04.006.
    1. Rodriguez JA, Betancourt JR, Sequist TD, Ganguli I. Differences in the use of telephone and video telemedicine visits during the COVID-19 pandemic. Am J Manag Care. 2021;27:21–26. doi: 10.37765/ajmc.2021.88573.
    1. Stifani BM, Smith A, Avila K, Levi EE, Benfield NC. Telemedicine for Contraceptive Counseling During the COVID-19 Pandemic: Referral Patterns and Attendance at Follow-Up Visits. Telemed J E Health. 2022 doi: 10.1089/tmj.2021.0498. Mar 14.
    1. Thompson TA, Sonalkar S, Butler JL, Grossman D. Telemedicine for Family Planning: A Scoping Review. Obstet Gynecol Clin North Am. 2020 doi: 10.1016/j.ogc.2020.02.004.
    1. Jain T, Schwarz EB, Mehrotra A. A study of telecontraception. N Engl J Med. 2019;381(13):1287–1288. doi: 10.1056/NEJMc1907545. Sep 26.
    1. Zuniga C, Grossman D, Harrell S, Blanchard K, Grindlay K. Breaking down barriers to birth control access: An assessment of online platforms prescribing birth control in the USA. J Telemed Telecare. 2020;26(6):322–331. doi: 10.1177/1357633X18824828. Epub 2019 Jan 21. PMID: 30665333.
    1. Zapata LB, Tregear SJ, Curtis KM, Tiller M, Pazol K, Mautone-Smith N, et al. Impact of Contraceptive Counseling in Clinical Settings: A Systematic Review. Am J Prev Med. 2015;49:S31–S45. doi: 10.1016/j.amepre.2015.03.023.
    1. Shin RJ, Yao M, Akesson C, Blazel M, Mei L, Brant AR. An exploratory study comparing the quality of contraceptive counseling provided via telemedicine versus in-person visits. Contraception. 2022 Mar 3;S0010-7824(22):00051–00053. doi: 10.1016/j.contraception.2022.02.004.
    1. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Reports Morb Mortal Wkly Report Recomm Reports. 2016;65:1–103. doi: 10.15585/mmwr.rr6503a1.
    1. Curtis KM, Jatlaoui TC, Tepper NK, Zapata LB, Horton LG, Jamieson DJ, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Reports Morb Mortal Wkly Report Recomm Reports. 2016;65:1–66. doi: 10.15585/mmwr.rr6504a1.
    1. Kennedy CE, Yeh PT, Gaffield ML, Brady M, Narasimhan M. Self-administration of injectable contraception: a systematic review and meta-analysis. BMJ Glob Heal. 2019;4 doi: 10.1136/bmjgh-2018-001350.
    1. Curtis KM, Nguyen A, Reeves JA, Clark EA, Folger SG, Whiteman MK. Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate. MMWR Morb Mortal Wkly Rep. 2021;70:739–743. doi: 10.15585/mmwr.mm7020a2.
    1. Katz M, Newmark RL, Aronstam A, O'Grady N, Strome S, Rafie S, et al. An implementation project to expand access to self-administered depot medroxyprogesterone acetate (DMPA) Contraception. 2020;102:392–395. doi: 10.1016/j.contraception.2020.09.001.
    1. Burlando AM, Flynn AN, Gutman S, McAllister A, Roe AH, Schreiber CA, et al. The Role of Subcutaneous Depot Medroxyprogesterone Acetate in Equitable Contraceptive Care: A Lesson From the Coronavirus Disease 2019 (COVID-19) Pandemic. Obstet Gynecol. 2021;138:574–577. doi: 10.1097/AOG.0000000000004524.
    1. ACOG Practice Bulletin No. 112: Emergency contraception. Obstet Gynecol. 2010;115:1100–1109. doi: 10.1097/AOG.0b013e3181deff2a.
    1. Turok DK, Gero A, Simmons RG, Kaiser JE, Stoddard GJ, Sexsmith CD, et al. Levonorgestrel vs. Copper Intrauterine Devices for Emergency Contraception. N Engl J Med. 2021;384:335–344. doi: 10.1056/NEJMoa2022141.
    1. FemCap How to determine which FemCapTM is right for you. 2020 Available from. [accessed January 1, 2022]
    1. HSPRx Enterprises Caya Contoured Diaphragm: Why Should You Prescribe Caya®? 2018 Available from. [accessed January 1, 2022]
    1. Mayer Labs Today Sponge. December 25, 2021 Available from. [accessed]
    1. Evofem PHEXXI (lactic acid, citric acid, and potassium bitartrate) vaginal gel. US FDA approved product information. 2020 Available from. [accessed January 1, 2022]
    1. Evans ML, Qasba N, Shah Arora K. COVID-19 highlights the policy barriers and complexities of postpartum sterilization. Contraception. 2021;103:3–5. doi: 10.1016/j.contraception.2020.10.006.
    1. Amico JR, Stimmel S, Hudson S, Gold M. “$231 … to pull a string!!!” American IUD users’ reasons for IUD self-removal: An analysis of internet forums. Contraception. 2020;101:393–398. doi: 10.1016/j.contraception.2020.02.005.
    1. Foster DG, Karasek D, Grossman D, Darney P, Schwarz EB. Interest in using intrauterine contraception when the option of self-removal is provided. Contraception. 2012;85:257–262. doi: 10.1016/j.contraception.2011.07.003.
    1. Foster DG, Grossman D, Turok DK, Peipert JF, Prine L, Schreiber CA, et al. Interest in and experience with IUD self-removal. Contraception. 2014;90:54–59. doi: 10.1016/j.contraception.2014.01.025.
    1. Stimmel S, Hudson S V, Gold M, Amico JR. Exploring the experience of IUD self-removal in the United States through posts on internet forums. Contraception. 2021 doi: 10.1016/j.contraception.2021.10.013.
    1. Broussard K, Becker A. Self-removal of long-acting reversible contraception: A content analysis of YouTube videos. Contraception. 2021;104:654–658. doi: 10.1016/j.contraception.2021.08.002.
    1. Wilkinson TA, Kottke MJ, Berlan ED. Providing Contraception for Young People During a Pandemic Is Essential Health Care. JAMA Pediatr. 2020;174:823–824. doi: 10.1001/jamapediatrics.2020.1884.
    1. Hill BJ, Lock L, Anderson B. Racial and ethnic differences in family planning telehealth use during the onset of the COVID-19 response in Arkansas, Kansas, Missouri, and Oklahoma. Contraception. 2021;104:262–264. doi: 10.1016/j.contraception.2021.05.016.
    1. Eberly LA, Kallan MJ, Julien HM, Haynes N, Khatana SAM, Nathan AS, et al. Patient Characteristics Associated With Telemedicine Access for Primary and Specialty Ambulatory Care During the COVID-19 Pandemic. JAMA Netw Open. 2020;3 doi: 10.1001/jamanetworkopen.2020.31640.
    1. Curtis KM, Nguyen A, Reeves JA, Clark EA, Folger SG, Whiteman MK, et al. Are We Reaching Everyone? A Cross-Sectional Study of Telehealth Inequity in the COVID-19 Pandemic in an Urban Academic Pediatric Primary Care Clinic. MMWR Morb Mortal Wkly Rep. 2021;70:262–264. doi: 10.15585/mmwr.mm7020a2.
    1. Naleway AL, Groom HC, Crawford PM, Salas SB, Henninger ML, Donald JL, et al. Incidence of SARS-CoV-2 Infection, Emergency Department Visits, and Hospitalizations Because of COVID-19 Among Persons Aged ≥12 Years, by COVID-19 Vaccination Status - Oregon and Washington, July 4-September 25, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1608–1612. doi: 10.15585/mmwr.mm7046a4.
    1. Shepherd DJ. Self-removal of a contraceptive implant. J Fam Plan Reprod Heal Care. 2012;38:208. doi: 10.1136/jfprhc-2012-100350.
    1. Jaffer K, Whalen S. Self removal of Implanon: a case report. J Fam Plan Reprod Heal Care. 2005;31:248. doi: 10.1783/1471189054483898.
    1. U.S. Food & Drug Administration COVID-19 vaccines. 2021 Available from. [accessed January 1, 2022]
    1. Centers for Disease Control and Prevention CDC Endorses ACIP's Updated COVID-19 Vaccine Recommendations. 2021 Available from. [accessed April 1, 2022]
    1. Centers for Disease Control and Prevention Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. 2021 Available from. [accessed April 1, 2022]
    1. Brown A. California to Require COVID Booster Shots for Health Care Workers. 2021 Available from. [accessed April 1, 2022]
    1. Musumeci M. Explaining the New COVID-19 Vaccination Requirement for Health Care Provider Staff. 2021 Available from. [accessed April 1, 2021]
    1. Centers for Disease Control and Prevention Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic. 2021 Available from. [accessed April 1, 2022]
    1. Godoy M. NPR; 2021 December 23. With omicron, you need a mask that means business. Available from. [accessed January 1, 2022]
    1. Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception. 1997;56:341–352.
    1. Bahamondes L, Faundes A, Sobreira-Lima B, Lui-Filho JF, Pecci P, Matera S. TCu 380A IUD: a reversible permanent contraceptive method in women over 35 years of age. Contraception. 2005;72:337–341. doi: 10.1016/j.contraception.2004.12.026.
    1. Ti AJ, Roe AH, Whitehouse KC, Smith RA, Gaffield ME, Curtis KM. Effectiveness and safety of extending intrauterine device duration: a systematic review. Am J Obstet Gynecol. 2020;223:24–35. doi: 10.1016/j.ajog.2020.01.014. e3.
    1. Wu JP, Pickle S. Extended use of the intrauterine device: a literature review and recommendations for clinical practice. Contraception. 2014;89:495–503. doi: 10.1016/j.contraception.2014.02.011.
    1. McNicholas C, Maddipati R, Zhao Q, Swor E, Peipert JF. Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the U.S. Food and Drug Administration-approved duration. Obstet Gynecol. 2015;125:599–604. doi: 10.1097/AOG.0000000000000690.
    1. Ali M, Akin A, Bahamondes L, Brache V, Habib N, Landoulsi S, et al. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant. Hum Reprod. 2016;31:2491–2498. doi: 10.1093/humrep/dew222.
    1. Centers for Disease Control and Prevention Symptoms of COVID-19. 2021 Available from. [accessed January 1, 2022]
    1. Centers for Disease Control and Prevention. CDC Updates and Shortens Recommended Isolation and Quarantine Period for General Population. 2021 Available from. [accessed January 1, 2022]
    1. Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18:1995–2002. doi: 10.1111/jth.14888.
    1. Llitjos J-F, Leclerc M, Chochois C, Monsallier J-M, Ramakers M, Auvray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020;18:1743–1746. doi: 10.1111/jth.14869.
    1. Wu C, Liu Y, Cai X, Zhang W, Li Y, Fu C. Prevalence of Venous Thromboembolism in Critically Ill Patients With Coronavirus Disease 2019: A Meta-Analysis. Front Med. 2021;8 doi: 10.3389/fmed.2021.603558.
    1. Kollias A, Kyriakoulis KG, Lagou S, Kontopantelis E, Stergiou GS, Syrigos K. Venous thromboembolism in COVID-19: A systematic review and meta-analysis. Vasc Med. 2021;26:415–425. doi: 10.1177/1358863X21995566.
    1. Mansory EM, Srigunapalan S, Lazo-Langner A. Venous Thromboembolism in Hospitalized Critical and Noncritical COVID-19 Patients: A Systematic Review and Meta-analysis. TH Open Companion J to Thromb Haemost. 2021;5:e286–e294. doi: 10.1055/s-0041-1730967.
    1. Cuker A, Tseng EK, Nieuwlaat R, Angchaisuksiri P, Blair C, Dane K, et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv. 2021;5:872–888. doi: 10.1182/bloodadvances.2020003763.
    1. Cuker A, Peyvandi F. COVID-19: Hypercoagulability. UpToDate. 2021 Version 63.
    1. Gervaise A, Bouzad C, Peroux E, Helissey C. Acute pulmonary embolism in non-hospitalized COVID-19 patients referred to CTPA by emergency department. Eur Radiol. 2020;30:6170–6177. doi: 10.1007/s00330-020-06977-5.
    1. Manzoli L, De Vito C, Marzuillo C, Boccia A, Villari P. Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis. Drug Saf. 2012;35:191–205. doi: 10.2165/11598050-000000000-00000.
    1. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ., 3rd Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143:697–706. doi: 10.7326/0003-4819-143-10-200511150-00006.
    1. Dinger JC, Heinemann LAJ, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007;75:344–354. doi: 10.1016/j.contraception.2006.12.019.
    1. Pomp ER, Rosendaal FR, Doggen CJM. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol. 2008;83:97–102. doi: 10.1002/ajh.21059.
    1. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5:692–699. doi: 10.1111/j.1538-7836.2007.02450.x.
    1. Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM. Progestin-only contraception and thromboembolism: A systematic review. Contraception. 2016;94:678–700. doi: 10.1016/j.contraception.2016.04.014.
    1. Chakhtoura Z, Canonico M, Gompel A, Thalabard J-C, Scarabin P-Y, Plu-Bureau G. Progestogen-only contraceptives and the risk of stroke: a meta-analysis. Stroke. 2009;40:1059–1062. doi: 10.1161/STROKEAHA.108.538405.
    1. Allen RH, Cwiak CA. 21st Editi. Ayer Company Publishers; New York, NY: 2018. Contraception for Women with Medical Conditions. Contracept. Technol; pp. 543–558.
    1. Food & Drug Administration Fact sheet for healthcare providers: emergency use authorization for Paxlovid. 2022 Available from. [accessed April 1, 2022]
    1. National Institutes of Health Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications. 2022 Available from: [Accessed May 1, 2022]
    1. Ouellet D, Hsu A, Qian J, Locke CS, Eason CJ, Cavanaugh JH, et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol. 1998;46:111–116. doi: 10.1046/j.1365-2125.1998.00749.x.
    1. Sekar VJ, Lefebvre E, Guzman SS, Felicione E, De Pauw M, Vangeneugden T, et al. Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women. Antivir Ther. 2008;13:563–569.
    1. Zhang J, Chung E, Yones C, Persson A, Mahnke L, Eley T, et al. The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. Antivir Ther. 2011;16:157–164. doi: 10.3851/IMP1724.
    1. Vogler MA, Patterson K, Kamemoto L, Park J-G, Watts H, Aweeka F, et al. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. J Acquir Immune Defic Syndr. 2010;55:473–482. doi: 10.1097/QAI.0b013e3181eb5ff5.
    1. Luque AE, Cohn SE, Park J-G, Cramer Y, Weinberg A, Livingston E, et al. Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of th. Antimicrob Agents Chemother. 2015;59:2094–2101. doi: 10.1128/AAC.04701-14.
    1. Vieira CS, Bahamondes M V, de Souza RM, Brito MB, Rocha Prandini TR, Amaral E, et al. Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women. J Acquir Immune Defic Syndr. 2014;66:378–385. doi: 10.1097/QAI.0000000000000189.
    1. DuBois BN, Atrio J, Stanczyk FZ, Cherala G. Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy. Contraception. 2015;91:71–75. doi: 10.1016/j.contraception.2014.08.009.
    1. Merck Fact sheet for healthcare providers: emergency use authorization for Lagevrio (molnupiravir) capsules. 2022 Available from. [accessed April 1, 2022]
    1. ACOG Committee opinion no. 530: access to postpartum sterilization. Obstet Gynecol. 2012;120:212–215. doi: 10.1097/AOG.0b013e318262e354.
    1. Zite N, Wuellner S, Gilliam M. Failure to obtain desired postpartum sterilization: risk and predictors. Obstet Gynecol. 2005;105:794–799. doi: 10.1097/01.AOG.0000157208.37923.17.
    1. Thurman AR, Janecek T. One-year follow-up of women with unfulfilled postpartum sterilization requests. Obstet Gynecol. 2010;116:1071–1077. doi: 10.1097/AOG.0b013e3181f73eaa.
    1. Boardman LA, DeSimone M, Allen RH. Barriers to completion of desired postpartum sterilization. R I Med J (2013) 2013;96:32–34.
    1. Zite N, Wuellner S, Gilliam M. Barriers to obtaining a desired postpartum tubal sterilization. Contraception. 2006;73:404–407. doi: 10.1016/j.contraception.2005.10.014.
    1. Centers for Disease Control and Prevention Clinical Questions About COVID-19 - which procedures are considered aerosol generating procedures in the healthcare setting? 2021 Available from. [accessed April 1, 2022]
    1. Tummers FH, Draaisma WA, Demirkiran A, Brouwer TA, Lagerveld BW, van Schrojenstein Lantman ES, et al. Potential Risk and Safety Measures in Laparoscopy in COVID-19 Positive Patients. Surg Innov. 2021 doi: 10.1177/15533506211003527.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren